Expression level of SET gene in acute myeloid leukemia and its clinical significance

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 35; no. 5; p. 397
• Main Authors: Ye, Peipei, Yu, Mengxia, Mu, Qitian, Chen, Feifei, Pei, Renzhi, Chen, Zhimei, Lou, Jiyu, Qian, Wenbin, Meng, Haitao, Tong, Hongyan, Mai, Wenyuan, Wang, Huanping, Jin, Jie
• Format: Journal Article
• Language: Chinese
• Published: China 01.05.2014
• Subjects: Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone Chaperones - genetics; Humans; Leukemia, Myeloid, Acute - genetics; Prognosis; Remission Induction; Transcription Factors - genetics
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2014.05.005

To investigate the expression level of SET gene in patients with acute myeloid leukemia (AML) and evaluate its significance. The expression level of SET gene in 141 de novo AML patients was determined by real time quantitative PCR (RQ-PCR), and its relationship with the clinical features and outcomes of these patients were analyzed. SET gene transcript level was detected in 141 AML patients with the median expression level of 0.86(range 0.02-15.69). AML patients with higher SET gene expression had a higher level of white blood cell (WBC ≥ 100 × 10⁹/L) count than of lower SET gene expression ones (31.0% vs 11.4%, P=0.005). In the 136 patients who received treatment after diagnosis, higher SET gene expression group had lower complete remission rate (50.0%) than of lower expression cohort (73.5%) after two cycles of chemotherapy (P=0.005). Survival analysis showed that patients with higher SET gene expression had significantly shorter overall survival(OS) (10 months vs 22 months, P=0.001) and event-free survival